Seeking Alpha: Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022 WHO classification of urinary tract tumors includes a list of less common subtypes (formerly known as variants) for ...
Renal & Urology News: Bladder Cancer Outcomes After RARC Worse With Trigone-Urethra Tumors
Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls. The ...
Nasdaq: Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
Nasdaq: Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...
Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
Mena FN: Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra ...
"Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2026"According to DelveInsight's report, the leading Non Muscle Invasive Bladder Cancer companies include CG Oncology, Janssen Research & ...